EDITORIAL SECTION
-
STRATEGY
Smarter Pharma
Quality management systems QMS are the backbone of pharmaceutical manufacturing ensuring safe products
-
RESEARCH DEVELOPMENT
Cytiva Laboratory capsule filters
Our singleuse selfcontained filtration solution
-
CLINICAL TRIALS
Why Clinical Trials Need Digital Endpoints
According Citeline the average success rate for bringing a Phase candidate to market has dropped to an alltime low of just
-
MANUFACTURING
Ensuring Quality and Compliance in Biopharma
Ensuring quality and regulatory compliance in the biopharmaceutical industry is critical to safeguarding product safety and efficacy
-
Information Technology
The Cost of Bad Data
Modern pharmaceutical research generates an unprecedented volume of information Data from genomic sequencing
-
Biopharma
Reimagining Global Biomanufacturing Capacity with Continuous and Modular Systems
Biotechnology is fueling the ongoing expansion of the global market for a broad array of goods
-
EXPERT Talk
Compliance to Competitive Advantage in Pharma Supply
Compliance gets you through an audit Resilience gets medicines to patients on the day something unexpected happens The DSCSAs enhanced requirements took effect November but real interoperability required three more rounds of accommodation phased implementation with the smalldispenser
Advisory Board
KNOWLEDGE BANK
-
Articles
Emerging Technologies in Automation Machinery for the Pharmaceutical Industry
Pharmaceutical industry has long been a forerunner on the use of technology where it has proved vital in increasing efficiency quality and safety Automation machinery has become more important over the years due to its ability to efficiently handle manufacturing packaging and distribution challenges Advanced technology is improving automation machinery as an integration tool in the pharmaceutical...
The Future of Pharma and CRO Operations: A Practical Guide to Automation
Many pharmaceutical leaders assume productivity gains will come from copilots conversational tools that help staff draft text or find information faster Yet copilots remain confined to the surface of work They assist with isolated tasks but cannot follow a process through to completion They do not manage clinical operations budgets or respond to RFPs for instance
Multi-Omics Integration: Accelerating Precision Drug Development
The economics of pharmaceutical RD are dominated by a single line item that never appears on a balance sheet the programmes that did not work Only about one clinical programme in ten reaches approval and the cost of the nine that do not is carried entirely by the one that does
Harnessing the Intracellular Machinery to Degrade Cellular Proteins
A countless number of proteins including growth factors receptors and cytokines play a pivotal role during the onset and exacerbation of numerous human diseases including cancer autoimmune and inflammatory disorders Of these proteins extracellular and membraneassociated proteins represent around of human proteome
Revolutionizing Healthcare: Gene Editing for Genetic Disorders with CRISPR Technology
Gene editing using CRISPR Clustered Regularly Interspaced Short Palindromic Repeats technology has the potential to revolutionize healthcare particularly in addressing genetic disorders
The Cost of Uncertainty: How Analytical Chemistry Drives Billion-Dollar Decisions in Pharma
In pharmaceutical development uncertainty is not an abstract scientific inconvenience It has a cost a timeline a regulatory consequence and ultimately a patient impact A promising medicine may have strong biological rationale compelling early data and significant commercial potential yet still face a fundamental question do we truly understand the product well enough to develop manufacture approve...
-
Techno Trends
Alume Biosciences Secures FDA Breakthrough Therapy Designation for Bevonescein
Alume Biosciences has received Breakthrough Therapy Designation BTD from the US Food and Drug Administration FDA for bevonescein an investigational fluorescent drug being developed to support realtime nerve visualisation during head and neck surgery in adults Bevonescein is an intravenous fluorescent peptidedye conjugate that binds to nerve tissue
-
Projects
SK pharmteco Plans More Than US$200 Million Investment in Small Molecule and Peptide Manufacturing
SK pharmteco is planning a fiveyear investment of more than US million to expand and modernise its pharmaceutical development and manufacturing operations in the United States The programme will strengthen capabilities for small molecules and peptides while supporting a more
-
Research Insights
One-month physicochemical stability study of idarubicin prepared in polyolefin-type bags for the treatment of hematological diseases
Idarubicine is a mainstay of the treatment strategy for hematological cancer The literature lacks stability data that comply with current preparation practices and recommendations for conducting stability studies
-
whitepaper
Post-Translational Modifications in Drug Discovery: From Molecular Regulation to Clinical Impact
For decades the central dogma of molecular biology has anchored our understanding of cellular function DNA to RNA to protein But this linear view is incomplete A growing body of evidence shows that much of biologys
TOP ARTICLES
-
1
The Future of Pharma and CRO Operations: A Practical Guide to Automation
Dr. Darko Matovski
Pharmaceutical productivity is shifting from copilots to Digital Workers - AI systems that execute and oversee end-to-end operations. Unlike task assistants, they manage compliant and cross-functional...
-
2
Multi-Omics Integration: Accelerating Precision Drug Development
Lakshmi
Roughly nine in ten clinical programmes fail, most often because the target was wrong. Multi-omics integration attacks that failure directly, asking whether independent molecular layers converge on th...
-
3
Harnessing the Intracellular Machinery to Degrade Cellular Proteins
Marco Pirisinu
Targeted protein degradation is an continuously growing technology specifically developed to degrade proteins within and outside the cells. Given the impact that these targets play in human pathology...
-
4
Revolutionizing Healthcare: Gene Editing for Genetic Disorders with CRISPR Technology
Harry Callum
CRISPR technology, with its precision in gene editing, revolutionizes healthcare by enabling personalized treatments for genetic disorders. It’s potential for correcting mutations, therapeutic a...
-
5
The Cost of Uncertainty: How Analytical Chemistry Drives Billion-Dollar Decisions in Pharma
Nithya Karakala
Analytical chemistry reduces uncertainty across pharmaceutical development by generating reliable data that supports critical decisions in quality, safety, manufacturing, and regulatory compliance. Ad...
press releases Read more...
MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid Tumors
MacroGenics Inc a clinicalstage biopharmaceutical company focused on developing innovative antibodybased therapeutics for the treatment of cancer today announced that the first patient has been dosed in the Phase study of MGC a firstinclass antibodydrug conjugate
Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapy
Legend Biotech Corporation a global leader in cell therapy today announced that the US Food and Drug Administration FDA has cleared the investigational new drug IND application for LB an investigational in vivo CART therapy designed to generate CDCD dualtargeting chimeric antigen receptor T
Eikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate Cancer
Eikon Therapeutics Inc a latestage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs today announced the submission of an Investigational New Drug IND application to the US Food and Drug Administration FDA to evaluate EIK for the t...
Orvida Pharma Announces FDA Acceptance of KM-023 (ontivatrep) into Rare Disease Evidence Principles Process for Olmsted Syndrome
Orvida Pharma a clinicalstage biotechnology company developing first and bestinclass treatments for rare and severe genetic skin diseases today announced that the US Food and Drug Administration FDA has accepted KM ontivatrep the Companys lead oral investigational therapy for Olmsted syndrome
Events Read more...
21 - 23
Oct 2026Drug Formulation & Drug Delivery 2026
Paris, France
21 - 22
Oct 2026Advance Clinical Trials and Research 2026
Paris, France
22 - 23
Oct 2026PDA Aseptic Symposium 2026
Congress Square Nakanoshima, O...
26 - 28
Oct 2026ACHEMA Middle East 2026
RICEC, Riyadh, KSA, Saudi Arab...
26 - 28
Oct 2026World Orphan Drug Congress
RAI, Amsterdam, Netherlands
27 - 28
Oct 2026Pharma Manufacturing & Automation Convention 2026
Novotel Hyderabad Airport, Ind...
28 - 30
Oct 2026BIOPLUS-INTERPHEX KOREA 2026
COEX, Seoul
02 - 04
Nov 2026Pharma Forum EMEA 2026
Dom Pedro Lisboa Hotel, Lisbon...
LATEST NEWS Read more...
AtomVie Global Radiopharma Announces Strategic Partnership with Jubilant Radiopharma to Strengthen Logistics and Distribution in Clinical Trials
AtomVie Global Radiopharma a global contract developer and manufacturer CDMO for radiopharmaceuticals today announced a strategic partnership with Jubilant DraxImage Inc operating as Jubilant Radiopharma Jubilant Radiopharma to provide logistics approval and lastmile distribution services to support
Transcripta Bio Announces Research Collaboration to Advance Discovery of New ALS Treatments
Transcripta Bio an AIpowered drug discovery company focused on neurological and neuromuscular diseases today announced a research collaboration and licensing agreement with Mayo Clinic centered on amyotrophic lateral sclerosis ALS a fatal neurodegenerative disease with few effective treatments
Insitro Announces a Strategic Collaboration with AstraZeneca for AI-enabled Discovery of Novel Therapeutics for MASH and Cardiomyopathies
Insitro an AI company unlocking causal human biology to systematically generate highvalue therapeutics to treat grievous illness today announced a worldwide exclusive research collaboration agreement with AstraZeneca to discover novel targets and therapeutics in metabolic dysfunctionassociated steat...
Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors
Vir Biotechnology Inc announced a collaboration and license agreement with Gilead to discover and engineer three novel PROXTEN dualmasked Tcell engager TCE development candidates targeting selected solid tumorassociated antigens Gilead will have an exclusive license to develop and commercialize
Genezen and Galibra Neuroscience Partner to Advance Gene Therapy for SSADH Deficiency Toward First-in-Human Trial
Genezen a gene therapy contract development and manufacturing organization CDMO and Galibra Neuroscience a biotechnology company developing transformative therapies for rare neurological disorders today announced a manufacturing partnership to advance Galibras GAL program an AAVbased gene therapy fo...
Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
Zealand Pharma AS a biotechnology company transforming the future of metabolic health today announced a multitarget strategic collaboration with Generate Biomedicines Inc Under the collaboration the companies intend to design and develop multispecific protein therapeutics




